MARKET

CYCCP

CYCCP

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.02
0.00
0.00%
Closed 16:00 09/17 EDT
OPEN
--
PREV CLOSE
8.02
HIGH
--
LOW
--
VOLUME
19
TURNOVER
--
52 WEEK HIGH
11.17
52 WEEK LOW
4.850
MARKET CAP
2.69M
P/E (TTM)
-2.3898
1D
5D
1M
3M
1Y
5Y
Cyclacel Pharmaceuticals Presenting at Three Conferences in September
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor confere...
GlobeNewswire · 09/08 11:00
BRIEF-Cyclacel Pharmaceuticals Inc - May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $50 Million From Time To Time
reuters.com · 08/12 21:38
BRIEF-Cyclacel Pharmaceuticals Reports Q2 Financial Results
reuters.com · 08/11 21:07
Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib -- Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow -- Cash Runway to Early 2023 -- Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET - BERKELEY HEIGH...
GlobeNewswire · 08/11 20:05
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 08/09 16:32
Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business updat...
GlobeNewswire · 08/03 11:00
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing
Benzinga · 07/13 11:05
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann's Virtua...
GlobeNewswire · 07/07 11:15
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYCCP. Analyze the recent business situations of Cyclacel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
David U'Prichard
President/Chief Executive Officer/Director
Spiro Rombotis
Vice Chairman/Director
Christopher Henney
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul McBarron
Senior Vice President
Mark Kirschbaum
Director
Brian Schwartz
Director
Karin Walker
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
Declaration Date
Dividend Per Share
Ex-Div Date
09/08/2021
Dividend USD 0.15
10/14/2021
--
Dividend USD 0.15
07/15/2021
--
Dividend USD 0.15
04/15/2021
12/11/2020
Dividend USD 0.15
01/14/2021
09/10/2020
Dividend USD 0.15
10/15/2020
06/25/2020
Dividend USD 0.15
07/16/2020
03/11/2020
Dividend USD 0.15
04/14/2020
12/10/2019
Dividend USD 0.15
01/16/2020
09/05/2019
Dividend USD 0.15
10/10/2019
05/29/2019
Dividend USD 0.15
07/11/2019
03/07/2019
Dividend USD 0.15
04/12/2019
12/11/2018
Dividend USD 0.15
01/11/2019
09/06/2018
Dividend USD 0.15
10/12/2018
05/31/2018
Dividend USD 0.15
07/12/2018
03/07/2018
Dividend USD 0.15
04/10/2018
12/06/2017
Dividend USD 0.15
01/11/2018
09/07/2017
Dividend USD 0.15
10/12/2017
05/30/2017
Dividend USD 0.15
07/12/2017
03/07/2017
Dividend USD 0.15
04/11/2017
12/07/2016
Dividend USD 0.15
01/13/2017
  • All
  • Financials
  • Insiders
More
About CYCCP
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.